Loading…
Loading…
VERX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for VERX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for VERX and 80,000+ other tickers.
See exactly how VERX's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VERX and 80,000+ other tickers.
Vertex, Inc. specializes in delivering advanced tax technology solutions to corporations across various sectors, including retail, communication, leasing, and manufacturing. These services are provided to clients both within the United States and globally. Its comprehensive product portfolio encompasses tools for tax determination, compliance and reporting, efficient tax data and document management, pre-built integration capabilities, and specialized solutions tailored to specific industries. Clients can access their software through traditional on-premise licenses or via cloud-based…
Shares of Vertex, Inc. (NASDAQ: VERX - Get Free Report) have received an average rating of "Hold" from the fifteen research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating on the
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance roles at leading healthcare companies, including more than 25 years at Boston Scientific Corporation, a medical device and healthcare technology company. Mr. Brennan retired last year from serving as Boston Scientific's Executive Vice President, Chief Fi.
APPLETON, Wis.--(BUSINESS WIRE)--IGEN, an industry leader in excise tax compliance automation, today announced an expansion of its strategic collaboration with Vertex, Inc., the Decision-to-Defense™ global indirect tax and compliance company. Together, the companies are bringing to the market a joint solution for a persistent challenge for tax teams: managing excise and global indirect tax as a single, connected process rather than as separate workstreams. For enterprises in highly regulated in.
Recognition highlights Vlasic's leadership of Vertex's enterprise AI and data transformation and her commitment to developing the next generation of women in technology Recognition highlights Vlasic's leadership of Vertex's enterprise AI and data transformation and her commitment to developing the next generation of women in technology
KING OF PRUSSIA, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that it will release third quarter 2026 financial results after the market close on Wednesday, November 4, 2026.